Table 1. **Characteristics of Nonsteroidal Drug Use among Controls***

Characteristic	No NSAID Use (n = 4491)	Celecoxib Use (n = 87)	Rofecoxib Use (n = 78)	Nonselective NSAID Use (n = 2144)
Sociodemographic				
Age, y	53.70 ± 9.61	58.61 ± 8.78†	58.06 ± 10.16‡	51.60 ± 8.86§
Insurance, n (%)		–†	–‡	–§
Medicare	462 (10.5)	17 (20.0)	16 (20.8)	188 (8.9)
Medicaid or Veterans Affairs	70 (1.6)	0 (0.0)	1 (1.3)	24 (1.1)
Private	3657 (83.6)	68 (80.0)	60 (77.9)	1827 (86.7)
None	187 (4.3)	0 (0.0)	0 (0.0)	69 (3.3)
Race, n (%)			–‡	–§
White	3583 (80.2)	68 (80.0)	71 (91.0)	1812 (84.8)
Black	699 (15.7)	12 (14.1)	7 (9.0)	266 (12.4)
Other	182 (4.1)	5 (5.9)	0 (0.0)	59 (2.8)
Duration of education, y	14.17 ± 2.45	13.59 ± 2.67†	14.29 ± 2.65	14.38 ± 2.40§
Clinical				
Physical activity score‖	7.42 ± 1.25	6.98 ± 1.31†	7.24 ± 1.24	7.43 ± 1.26
BMI, kg/m²	27.20 ± 5.52	29.71 ± 6.28†	28.04 ± 5.81	27.70 ± 6.02§
Cigarette smoking, n (%)			–‡	
Past	1476 (33.0)	38 (43.7)	33 (42.9)	680 (31.8)
Current	949 (21.2)	15 (17.2)	5 (6.5)	426 (19.9)
Diabetes mellitus, n (%)	360 (8.0)	12 (13.8)	10 (12.8)	142 (6.6)§
Family history of coronary disease, n (%)	1559 (34.7)	28 (32.2)	29 (37.2)	783 (36.6)
Women, n (%)	2462 (54.8)	60 (69.0)	51 (65.4)	1418 (66.1)§
History of congestive heart failure, n (%)	49 (1.1)	5 (5.7)†	1 (1.3)	14 (0.7)
Hypercholesterolemia, n (%)	1295 (28.9)	37 (42.5)†	26 (33.3)	562 (26.2)§
Hypertension, n (%)	1420 (31.6)	44 (50.6)†	33 (42.3)‡	632 (29.5)
Previous angina or coronary disease, n (%)	197 (4.4)	10 (11.5)†	5 (6.4)	94 (4.4)
Self-reported osteoarthritis, n (%)	304 (6.8)	40 (46.0)†	31 (39.7)‡	207 (9.7)§
Self-reported rheumatoid arthritis, n (%)	126 (2.8)	13 (14.9)†	10 (12.8)‡	86 (4.0)§
Self-reported renal disease, n (%)	18 (0.4)	0 (0.0)	0 (0.0)	5 (0.2)
History of gastrointestinal ulcer disease, n (%)	280 (6.2)	7 (8.0)	4 (5.2)	112 (5.2)
Medication use, n (%)				
ACE inhibitors	454 (10.1)	10 (11.5)	12 (15.4)	167 (7.8)
Aspirin	1295 (28.8)	24 (27.6)	25 (32.1)	465 (21.7)§
β-Blockers	392 (8.7)	14 (16.1)†	8 (10.3)	141 (6.6)§
Calcium-channel blockers	427 (9.5)	17 (19.5)	11 (14.1)	150 (7.0)§
Diuretics	409 (9.1)	17 (19.5)†	11 (14.1)‡	204 (9.4)
HMG-CoA reductase inhibitors	551 (12.3)	27 (31.0)†	18 (23.1)‡	196 (9.1)§
Physician visits per y, n	4.76 ± 9.24	9.63 ± 12.76†	10.73 ± 14.31‡	4.83 ± 9.94

* Values expressed with a plus/minus sign are means ± SD. ACE = angiotensin-converting enzyme; BMI = body mass index; HMG-CoA = 3-hydroxy-3-methylglutaryl coenzyme A; NSAID = nonsteroidal anti-inflammatory drug.
† $P < 0.05$ comparing celecoxib with no NSAIDs.
‡ $P < 0.05$ comparing rofecoxib with no NSAIDs.
§ $P < 0.05$ comparing nonselective NSAIDs with no NSAIDs.
‖ Validated physical activity score (25). Higher score represents greater physical activity.